The authors present a case of extensive primary intramedullary spinal CNS ganglioneuroblastoma (GNB) in a 23-year-old man. Central nervous system GNB is a poorly differentiated neuroepithelial tumor composed of neuroblasts and differentiated ganglion cells, and these lesions are extremely uncommon. Most previously reported primary intraaxial neuroblastic tumors were described in the brain. There has been only one other report of primary spinal cord CNS GNB published to date; the clinical course and prognosis for primary spinal cord tumors of this type are unknown. Similar tumor types demonstrate poor prognoses.
This 23-year-old man presented after 9 months of progressive myelopathy. Admission MR imaging showed an intraaxial enhancing mass extending from C-3 to the conus medullaris, with a holocord appearance in several areas. Due to the tumor size, operative intervention was initially limited to biopsy sampling. Chemotherapy resulted in histological maturation, but initial tumor regression was temporary. The patient suffered progressive quadriparesis, and neuroimaging demonstrated slow enlargement of the tumor and an associated syrinx. Nineteen months after diagnosis, the tumor was excised to gross-total resection in a 2-stage operation. One year following resection, the patient had no radiographic recurrence and was functional in a wheelchair with minimal paresis in the upper extremities. This case represents the most extensive example of primary spinal intramedullary CNS GNB reported to date. Holocord tumors present a significant challenge to the neurosurgeon, and resection bears substantial risk of morbidity. In spinal cord CNS GNB, chemotherapy followed by complete resection may be the most effective means of tumor control.
Abbreviations used in this paper: GNB = ganglioneuroblastoma; MEP = motor evoked potential; NB = neuroblastoma; PNET = primitive neuroectodermal tumor.
Central Brain Tumor Registry of the United States: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2007. (http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf) [Accessed May 11 2011]
EvansAEJenkinRDSpostoROrtegaJAWilsonCBWaraW: The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg72:572–5821990
GotoSUmeharaSGerbingRBStramDOBrodeurGMSeegerRC: Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer92:2699–27082001
GouldVERorkeLBJanssonDSMolenaarWMTrojanowskiJQLeeVM: Primitive neuroectodermal tumors of the central nervous system express neuroendocrine markers and may express all classes of intermediate filaments. Hum Pathol21:245–2521990
MatthayKKReynoldsCPSeegerRCShimadaHAdkinsESHaas-KoganD: Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol27:1007–10132009
Quiñones-HinojosaALyonRZadaGLambornKRGuptaNParsaAT: Changes in transcranial motor evoked potentials during intramedullary spinal cord tumor resection correlate with postoperative motor function. Neurosurgery56:982–9932005
ZeltzerPMBoyettJMFinlayJLAlbrightALRorkeLBMilsteinJM: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol17:832–8451999